Welcome to our dedicated page for Chemed SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Chemed Corporation’s (NYSE: CHE) SEC filings, including Current Reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. Chemed is a Delaware-incorporated holding company headquartered in Cincinnati, Ohio, operating VITAS Healthcare and Roto-Rooter as wholly owned subsidiaries.
For investors analyzing Chemed’s hospice operations, filings and related exhibits can offer detail on VITAS Healthcare’s net patient revenue, average daily census, admissions, and the impact of Medicare reimbursement rates and Medicare Cap billing limitations. Management’s discussion of these topics in earnings releases, which are often furnished as exhibits to Form 8-K, helps explain how regulatory and reimbursement factors influence segment performance.
Filings also shed light on Roto-Rooter’s plumbing, drain cleaning, water restoration, and water cleanup services. Segment disclosures in attached earnings releases describe revenue trends across commercial and residential customers, gross margins, selling, general and administrative expenses, and adjusted EBITDA margins. These details help readers understand how demand for plumbing and drain cleaning services affects Chemed’s consolidated results.
Chemed’s SEC filings may address capital structure and capital allocation, including its Amended and Restated Credit Agreement, share repurchase authorizations, and long-running dividend program. They can also disclose material events such as updates to earnings guidance, executive leadership changes, or other significant corporate developments.
On this page, AI-powered tools summarize lengthy filings and attached press releases, highlighting items such as quarterly earnings (often reported via Form 8-K), non-GAAP measures like EBITDA and Adjusted Diluted EPS, and regulatory or reimbursement disclosures relevant to VITAS and Roto-Rooter. Users can also review insider- and management-related information when it appears in current reports or other SEC documents.
CHEMED CORP director Patrick P. Grace sold shares in an open-market trade. On this transaction date, he sold 60 shares of Chemed Capital Stock at an average price of $425.78 per share. After the sale, he directly owned 3,337 shares, so the transaction represented only a small portion of his holdings.
Chemed Corporation president and CEO Kevin J. McNamara reported an open-market sale of 2,000 shares of Chemed Capital Stock. The weighted average sale price was $421.13 per share, with individual trades executed between $418.99 and $424.95. Following this transaction, McNamara directly holds 90,219 shares of Chemed stock.
Chemed Corporation filed a Form 144 reporting proposed sales of Common Stock by an identified holder. The notice lists a proposed block of 1,000 shares through Merrill Lynch with an entry dated 05/01/2026. The filing also records prior stock awards/exercises dated 08/02/2024 (682 shares) and 10/30/2023 (318 shares). Recent sales reported in the past three months list transactions of 1,000, 1,000 and 1,500 shares on 03/12/2026 and 03/27/2026 with corresponding numeric entries shown in the excerpt.
Kevin J. McNamara filed a Form 144 reporting proposed dispositions of Common Stock of CHE. The filing lists sales dated 03/12/2026 (1,000 shares, $404,244.00 and 1,000 shares, $402,050.00) and 03/27/2026 (1,500 shares, $558,855.00).
Chemed Corp Schedule 13G: Vanguard Capital Management reports beneficial ownership of 744,055 shares of Common Stock, representing 5.40% of the class as of 03/31/2026. The filer reports sole voting power over 107,985 shares and sole dispositive power over 744,055 shares.
The filing is signed by Vanguard's Head of Global Fund Administration on 04/29/2026 and describes holdings that include securities held by Vanguard funds and managed accounts.
Vanguard Portfolio Management reported beneficial ownership of 817,550 shares of Chemed Corp common stock, equal to 5.93% of the class. The filer states sole dispositive power over 817,550 shares and sole voting power for 1,851 shares. The filing is signed on 04/29/2026.
Chemed Corporation reported first-quarter 2026 service revenues and sales of $657.5 million, up modestly from $646.9 million a year earlier. Net income was $66.3 million versus $71.8 million, as higher costs and expenses offset revenue growth.
Hospice segment VITAS generated net revenue of $420.0 million, driven by a 2.2% increase in days of care and Medicare rate increases. Roto-Rooter revenue was $237.5 million, slightly below last year, with softer water restoration and contractor activity despite higher pricing in core plumbing and drain services.
The company produced net cash from operating activities of $88.2 million, used $190.0 million to repurchase 500,000 shares, and ended the quarter with $91.2 million of long-term debt under its revolving credit facility and $16.9 million of cash and cash equivalents.
Chemed Corporation reported first-quarter 2026 revenue of $657.5 million, up slightly from $646.9 million a year earlier, with net income of $66.3 million and diluted EPS of $4.84 versus $4.86. Adjusted diluted EPS rose to $5.65 from $5.63.
VITAS revenue grew 3.1% to $420.0 million, driven by 2.2% higher days-of-care and Medicare rate increases, while Roto-Rooter revenue slipped 0.9% to $237.5 million and its adjusted EBITDA margin fell. Chemed bought San Francisco and Fort Worth Roto-Rooter franchises for $20.6 million and repurchased 500,000 shares for $197.7 million.
Management raised full-year 2026 guidance, now expecting adjusted EPS of $24.00–$24.75, whose midpoint is a 13% increase over 2025’s $21.55 and above the prior 2026 range of $23.25–$24.25. VITAS growth and margins were revised upward, while Roto-Rooter’s adjusted EBITDA margin outlook was trimmed due to higher marketing costs.
Chemed Corporation entered into a new five-year $450 million senior secured revolving credit facility, documented in a Sixth Amended and Restated Credit Agreement. The facility includes a $100 million letters of credit sublimit and an accordion feature of up to $250 million in additional revolving capacity.
Borrowings bear interest at a floating rate based on the secured overnight financing rate (SOFR) plus a tiered margin that depends on Chemed’s leverage ratio. JPMorgan Chase Bank serves as Administrative Agent and Joint Lead Arranger, with Bank of America, PNC Bank and U.S. Bank in key syndicate roles.